Menu Search
Equities

Cosmo Pharmaceuticals NV

  • Add to watchlist
  • Add to portfolio
  • Add an alert
C43:BRN

Cosmo Pharmaceuticals NV

Actions
  • Price (CHF)117.48
  • Today's Change0.00 / 0.00%
  • Shares traded3.00
  • 1 Year change--
  • Beta1.5106
Data delayed at least 15 minutes, as of Jan 27 2026.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Cosmo Pharmaceuticals NV grew revenues 187.55% from 92.78m to 266.79m while net income improved from a loss of 10.78m to a gain of 133.24m.
Gross margin73.79%
Net profit margin30.23%
Operating margin33.20%
Return on assets8.83%
Return on equity11.52%
Return on investment9.60%
More ▼

Cash flow in EURView more

In 2024, cash reserves at Cosmo Pharmaceuticals NV fell by 5.98m. However, the company earned 162.41m from its operations for a Cash Flow Margin of 60.88%. In addition the company used 128.88m on investing activities and also paid 40.22m in financing cash flows.
Cash flow per share3.69
Price/Cash flow per share31.87
Book value per share26.16
Tangible book value per share6.09
More ▼

Balance sheet in EURView more

Cosmo Pharmaceuticals NV uses little debt in its capital structure as supported by a debt to capital ratio of 0.58%.
Current ratio3.84
Quick ratio3.59
Total debt/total equity0.0059
Total debt/total capital0.0058
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.